 David Bentley
Concepts (535)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA Polymerase II | 60 | 2025 | 324 | 11.160 |
Why?
| | Transcription, Genetic | 61 | 2025 | 1457 | 6.850 |
Why?
| | RNA Precursors | 17 | 2023 | 154 | 4.450 |
Why?
| | RNA, Messenger | 35 | 2021 | 2834 | 3.810 |
Why?
| | RNA Processing, Post-Transcriptional | 16 | 2021 | 92 | 3.650 |
Why?
| | Transcription Termination, Genetic | 5 | 2025 | 19 | 3.490 |
Why?
| | RNA Splicing | 17 | 2023 | 269 | 2.580 |
Why?
| | Transcription Elongation, Genetic | 6 | 2018 | 23 | 2.330 |
Why?
| | Nuclear Proteins | 13 | 2025 | 712 | 2.210 |
Why?
| | Saccharomyces cerevisiae Proteins | 13 | 2017 | 405 | 2.200 |
Why?
| | RNA-Binding Proteins | 12 | 2025 | 422 | 2.130 |
Why?
| | Histones | 9 | 2018 | 636 | 1.790 |
Why?
| | Poly A | 9 | 2022 | 51 | 1.780 |
Why?
| | Transcriptional Elongation Factors | 6 | 2022 | 40 | 1.680 |
Why?
| | Saccharomyces cerevisiae | 12 | 2022 | 557 | 1.630 |
Why?
| | Protein Phosphatase 1 | 2 | 2025 | 33 | 1.570 |
Why?
| | Exoribonucleases | 4 | 2019 | 49 | 1.490 |
Why?
| | Cyclin-Dependent Kinases | 9 | 2025 | 132 | 1.360 |
Why?
| | Alternative Splicing | 8 | 2021 | 229 | 1.350 |
Why?
| | Promoter Regions, Genetic | 17 | 2024 | 1251 | 1.280 |
Why?
| | DNA-Binding Proteins | 11 | 2025 | 1502 | 1.260 |
Why?
| | RNA 3' End Processing | 6 | 2018 | 11 | 1.260 |
Why?
| | HEK293 Cells | 11 | 2025 | 730 | 1.160 |
Why?
| | mRNA Cleavage and Polyadenylation Factors | 7 | 2018 | 29 | 1.030 |
Why?
| | Chromatin | 8 | 2017 | 519 | 0.930 |
Why?
| | Transcriptional Activation | 5 | 2018 | 378 | 0.910 |
Why?
| | Protein Processing, Post-Translational | 4 | 2019 | 465 | 0.900 |
Why?
| | Phosphorylation | 16 | 2025 | 1759 | 0.880 |
Why?
| | RNA | 7 | 2021 | 921 | 0.880 |
Why?
| | Polyadenylation | 3 | 2022 | 42 | 0.830 |
Why?
| | RNA Caps | 8 | 2014 | 35 | 0.830 |
Why?
| | Mutation | 25 | 2022 | 3959 | 0.770 |
Why?
| | Transcription Factor TFIIH | 6 | 2020 | 37 | 0.710 |
Why?
| | Transcription Initiation, Genetic | 2 | 2018 | 15 | 0.690 |
Why?
| | HeLa Cells | 11 | 2025 | 636 | 0.620 |
Why?
| | Cell Line | 17 | 2025 | 2847 | 0.620 |
Why?
| | Chromatin Assembly and Disassembly | 3 | 2017 | 104 | 0.610 |
Why?
| | DNA, Fungal | 2 | 2017 | 80 | 0.610 |
Why?
| | Transcription Factors | 13 | 2012 | 1719 | 0.610 |
Why?
| | RNA Cleavage | 1 | 2018 | 10 | 0.600 |
Why?
| | Introns | 5 | 2023 | 258 | 0.600 |
Why?
| | Models, Genetic | 8 | 2015 | 600 | 0.600 |
Why?
| | Yeasts | 5 | 2011 | 53 | 0.550 |
Why?
| | RNA, Catalytic | 2 | 2009 | 187 | 0.520 |
Why?
| | Nucleosomes | 2 | 2011 | 155 | 0.510 |
Why?
| | Cell Nucleus | 6 | 2022 | 620 | 0.500 |
Why?
| | Kinetics | 6 | 2019 | 1670 | 0.500 |
Why?
| | Methyltransferases | 3 | 2004 | 78 | 0.500 |
Why?
| | Genome, Human | 6 | 2022 | 425 | 0.490 |
Why?
| | Recombinant Fusion Proteins | 4 | 2016 | 665 | 0.480 |
Why?
| | Transcription Factors, TFII | 5 | 2012 | 41 | 0.460 |
Why?
| | Protein Engineering | 1 | 2016 | 97 | 0.460 |
Why?
| | Exons | 11 | 2021 | 355 | 0.450 |
Why?
| | Polymerase Chain Reaction | 4 | 2021 | 1062 | 0.450 |
Why?
| | DNA Polymerase II | 3 | 2005 | 37 | 0.440 |
Why?
| | Binding Sites | 11 | 2019 | 1303 | 0.440 |
Why?
| | Terminator Regions, Genetic | 5 | 2006 | 12 | 0.440 |
Why?
| | RNA, Fungal | 2 | 2011 | 72 | 0.440 |
Why?
| | Exonucleases | 2 | 2022 | 9 | 0.430 |
Why?
| | Humans | 80 | 2025 | 137782 | 0.420 |
Why?
| | Genes, myc | 5 | 2007 | 48 | 0.410 |
Why?
| | Oocytes | 10 | 2005 | 181 | 0.400 |
Why?
| | Protein Binding | 7 | 2025 | 2224 | 0.400 |
Why?
| | RNA Stability | 2 | 2012 | 117 | 0.400 |
Why?
| | Nucleotidyltransferases | 4 | 2004 | 28 | 0.400 |
Why?
| | Protein Kinases | 3 | 2010 | 319 | 0.380 |
Why?
| | Genes, Fungal | 2 | 2010 | 52 | 0.380 |
Why?
| | Gene Expression Regulation, Fungal | 4 | 2017 | 72 | 0.370 |
Why?
| | Protein Structure, Tertiary | 10 | 2015 | 861 | 0.360 |
Why?
| | Phosphoprotein Phosphatases | 2 | 2009 | 67 | 0.350 |
Why?
| | Fungal Proteins | 5 | 2011 | 123 | 0.350 |
Why?
| | Animals | 38 | 2024 | 36951 | 0.350 |
Why?
| | Phosphoserine | 1 | 2010 | 34 | 0.340 |
Why?
| | Whole Genome Sequencing | 5 | 2022 | 160 | 0.330 |
Why?
| | Neoplasm Proteins | 3 | 2007 | 434 | 0.330 |
Why?
| | Dichlororibofuranosylbenzimidazole | 6 | 2009 | 8 | 0.320 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2022 | 74 | 0.310 |
Why?
| | Histone-Lysine N-Methyltransferase | 3 | 2017 | 136 | 0.310 |
Why?
| | RNA Folding | 2 | 2021 | 38 | 0.310 |
Why?
| | Spliceosomes | 3 | 2023 | 48 | 0.300 |
Why?
| | Repressor Proteins | 4 | 2022 | 427 | 0.300 |
Why?
| | Genes, Regulator | 3 | 2004 | 37 | 0.290 |
Why?
| | RNA Splice Sites | 3 | 2021 | 45 | 0.280 |
Why?
| | Molecular Sequence Data | 14 | 2014 | 2900 | 0.270 |
Why?
| | Ovarian Neoplasms | 5 | 2015 | 565 | 0.260 |
Why?
| | Ubiquitination | 2 | 2024 | 102 | 0.240 |
Why?
| | Macromolecular Substances | 5 | 2010 | 229 | 0.240 |
Why?
| | Peptide Elongation Factors | 2 | 2022 | 15 | 0.230 |
Why?
| | Cyclin-Dependent Kinase 8 | 1 | 2025 | 43 | 0.220 |
Why?
| | Lysine | 1 | 2007 | 294 | 0.220 |
Why?
| | RNA Cap-Binding Proteins | 1 | 2004 | 4 | 0.220 |
Why?
| | DNA-Directed RNA Polymerases | 2 | 1997 | 57 | 0.220 |
Why?
| | RNA Polymerase III | 2 | 2017 | 28 | 0.210 |
Why?
| | DNA, Neoplasm | 2 | 2015 | 164 | 0.210 |
Why?
| | Gene Expression Regulation | 9 | 2025 | 2607 | 0.210 |
Why?
| | RNA Editing | 3 | 2009 | 24 | 0.210 |
Why?
| | Interferons | 1 | 2025 | 202 | 0.210 |
Why?
| | Methylation | 3 | 2011 | 230 | 0.210 |
Why?
| | Amino Acid Sequence | 9 | 2014 | 2139 | 0.200 |
Why?
| | RNA, Antisense | 1 | 2022 | 17 | 0.200 |
Why?
| | Models, Biological | 5 | 2020 | 1783 | 0.200 |
Why?
| | Chromatin Immunoprecipitation | 3 | 2012 | 138 | 0.200 |
Why?
| | Signal Transduction | 5 | 2025 | 5081 | 0.190 |
Why?
| | Base Sequence | 13 | 2015 | 2181 | 0.190 |
Why?
| | Models, Theoretical | 1 | 2006 | 578 | 0.190 |
Why?
| | Protein Kinase Inhibitors | 3 | 2025 | 916 | 0.190 |
Why?
| | Nucleotides | 1 | 2022 | 125 | 0.190 |
Why?
| | Immunoglobulin Variable Region | 2 | 2017 | 80 | 0.180 |
Why?
| | Ultraviolet Rays | 2 | 2018 | 396 | 0.180 |
Why?
| | Gene Products, tat | 2 | 1998 | 23 | 0.180 |
Why?
| | Chromosomal Proteins, Non-Histone | 2 | 2003 | 126 | 0.180 |
Why?
| | Mice | 14 | 2018 | 17794 | 0.180 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2017 | 1396 | 0.170 |
Why?
| | Rare Diseases | 1 | 2021 | 104 | 0.170 |
Why?
| | HCT116 Cells | 2 | 2018 | 80 | 0.170 |
Why?
| | Proto-Oncogenes | 3 | 1989 | 29 | 0.170 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 2 | 2014 | 62 | 0.170 |
Why?
| | Nerve Tissue Proteins | 3 | 2022 | 596 | 0.170 |
Why?
| | Transfection | 7 | 2007 | 945 | 0.160 |
Why?
| | Xenopus | 6 | 2003 | 87 | 0.160 |
Why?
| | HIV-2 | 2 | 1997 | 18 | 0.160 |
Why?
| | Adenosine Triphosphatases | 2 | 2012 | 168 | 0.160 |
Why?
| | Peptide Chain Elongation, Translational | 2 | 1998 | 18 | 0.150 |
Why?
| | 3' Flanking Region | 1 | 2018 | 7 | 0.150 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenases | 2 | 2009 | 13 | 0.150 |
Why?
| | Breast Neoplasms | 5 | 2017 | 2253 | 0.150 |
Why?
| | Hydrolysis | 2 | 2011 | 177 | 0.150 |
Why?
| | Host-Pathogen Interactions | 1 | 2022 | 364 | 0.150 |
Why?
| | Phenanthrenes | 1 | 2018 | 13 | 0.150 |
Why?
| | Metallothionein | 1 | 1998 | 25 | 0.150 |
Why?
| | Diterpenes | 1 | 2018 | 31 | 0.150 |
Why?
| | Coloboma | 1 | 2018 | 5 | 0.150 |
Why?
| | Epoxy Compounds | 1 | 2018 | 33 | 0.150 |
Why?
| | Isotonic Solutions | 1 | 2018 | 38 | 0.150 |
Why?
| | Coenzymes | 1 | 1998 | 19 | 0.150 |
Why?
| | Saline Solution, Hypertonic | 1 | 2018 | 41 | 0.150 |
Why?
| | Nystagmus, Pathologic | 1 | 2018 | 13 | 0.150 |
Why?
| | PAX6 Transcription Factor | 1 | 2018 | 21 | 0.150 |
Why?
| | Down Syndrome | 1 | 2025 | 497 | 0.140 |
Why?
| | Genes | 5 | 2004 | 230 | 0.140 |
Why?
| | Zebrafish Proteins | 1 | 2001 | 288 | 0.140 |
Why?
| | Proto-Oncogene Proteins | 4 | 2017 | 648 | 0.140 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2017 | 9 | 0.140 |
Why?
| | Cell Cycle Proteins | 3 | 2003 | 617 | 0.140 |
Why?
| | Receptors, Estrogen | 2 | 2017 | 436 | 0.140 |
Why?
| | Cytidine Deaminase | 2 | 2017 | 61 | 0.140 |
Why?
| | Serine | 3 | 2009 | 141 | 0.130 |
Why?
| | 3' Untranslated Regions | 3 | 2022 | 145 | 0.130 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2017 | 83 | 0.130 |
Why?
| | Enzyme Inhibitors | 2 | 2003 | 840 | 0.130 |
Why?
| | Progestins | 1 | 2017 | 79 | 0.130 |
Why?
| | Trans-Activators | 2 | 2002 | 398 | 0.130 |
Why?
| | Xenopus laevis | 4 | 2004 | 106 | 0.130 |
Why?
| | Genetic Diseases, Inborn | 2 | 2015 | 44 | 0.130 |
Why?
| | Plasmids | 5 | 2006 | 363 | 0.120 |
Why?
| | Tetrahydrofolate Dehydrogenase | 1 | 2016 | 23 | 0.120 |
Why?
| | Brain Neoplasms | 2 | 2015 | 1239 | 0.120 |
Why?
| | Critical Illness | 1 | 2022 | 815 | 0.120 |
Why?
| | Drosophila Proteins | 2 | 2003 | 204 | 0.120 |
Why?
| | Spinal Neoplasms | 1 | 2015 | 32 | 0.120 |
Why?
| | Protein Domains | 1 | 2017 | 289 | 0.120 |
Why?
| | Cataract | 1 | 2018 | 213 | 0.120 |
Why?
| | Tetraploidy | 1 | 2015 | 6 | 0.120 |
Why?
| | Clonal Evolution | 1 | 2015 | 45 | 0.120 |
Why?
| | Receptors, Progesterone | 1 | 2017 | 350 | 0.120 |
Why?
| | Recombinational DNA Repair | 1 | 2015 | 16 | 0.120 |
Why?
| | Genes, p53 | 1 | 2015 | 72 | 0.120 |
Why?
| | Chromosomes, Human | 1 | 2015 | 44 | 0.120 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2015 | 83 | 0.120 |
Why?
| | HIV-1 | 2 | 1998 | 864 | 0.110 |
Why?
| | Genome-Wide Association Study | 4 | 2022 | 1431 | 0.110 |
Why?
| | Neoplasms | 3 | 2021 | 2673 | 0.110 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2007 | 283 | 0.110 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2015 | 59 | 0.110 |
Why?
| | CRISPR-Cas Systems | 1 | 2016 | 125 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2015 | 539 | 0.110 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2015 | 105 | 0.110 |
Why?
| | Immunoglobulin M | 1 | 2015 | 289 | 0.110 |
Why?
| | Escherichia coli Proteins | 1 | 2016 | 200 | 0.110 |
Why?
| | Granulomatous Disease, Chronic | 2 | 1991 | 55 | 0.110 |
Why?
| | Deoxycytidine | 2 | 2015 | 179 | 0.100 |
Why?
| | Histone Chaperones | 1 | 2013 | 16 | 0.100 |
Why?
| | Cyclin-Dependent Kinase 9 | 2 | 2012 | 10 | 0.100 |
Why?
| | Antibodies | 4 | 2006 | 410 | 0.100 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2013 | 49 | 0.100 |
Why?
| | Lymphocytes | 1 | 2015 | 397 | 0.100 |
Why?
| | Chloramphenicol O-Acetyltransferase | 3 | 1997 | 38 | 0.100 |
Why?
| | Long QT Syndrome | 1 | 2014 | 70 | 0.100 |
Why?
| | Potassium Channels | 1 | 2014 | 151 | 0.100 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2013 | 77 | 0.100 |
Why?
| | Time Factors | 5 | 2017 | 6834 | 0.100 |
Why?
| | Cell Line, Tumor | 5 | 2014 | 3415 | 0.090 |
Why?
| | Globins | 3 | 1997 | 22 | 0.090 |
Why?
| | Sequence Deletion | 2 | 2003 | 183 | 0.090 |
Why?
| | Quantitative Trait Loci | 1 | 2014 | 380 | 0.090 |
Why?
| | Carcinogenesis | 1 | 2013 | 217 | 0.090 |
Why?
| | Ovary | 1 | 2013 | 221 | 0.090 |
Why?
| | beta-Globins | 1 | 2011 | 8 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-myc | 3 | 2009 | 139 | 0.090 |
Why?
| | Ribonucleoproteins, Small Nuclear | 1 | 2011 | 24 | 0.090 |
Why?
| | Escherichia coli | 1 | 2016 | 815 | 0.090 |
Why?
| | Protein Interaction Mapping | 1 | 2012 | 109 | 0.090 |
Why?
| | DNA | 6 | 2005 | 1459 | 0.090 |
Why?
| | Plasma | 1 | 2013 | 212 | 0.090 |
Why?
| | Glioblastoma | 1 | 2015 | 346 | 0.090 |
Why?
| | Repetitive Sequences, Amino Acid | 2 | 2001 | 17 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2014 | 430 | 0.090 |
Why?
| | Chromatography, Affinity | 2 | 2002 | 88 | 0.090 |
Why?
| | Recombinant Proteins | 4 | 1998 | 1356 | 0.090 |
Why?
| | Isoquinolines | 2 | 2004 | 43 | 0.090 |
Why?
| | NADH, NADPH Oxidoreductases | 1 | 1990 | 18 | 0.090 |
Why?
| | DNA Helicases | 3 | 1997 | 145 | 0.090 |
Why?
| | Genes, Reporter | 2 | 2003 | 269 | 0.080 |
Why?
| | RNA, Untranslated | 1 | 2011 | 124 | 0.080 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2010 | 94 | 0.080 |
Why?
| | Chromosome Deletion | 4 | 1992 | 115 | 0.080 |
Why?
| | Hepatitis Delta Virus | 1 | 2009 | 7 | 0.080 |
Why?
| | Myocytes, Cardiac | 1 | 2014 | 526 | 0.080 |
Why?
| | Epilepsy | 1 | 2014 | 333 | 0.080 |
Why?
| | Cricetulus | 1 | 2009 | 109 | 0.080 |
Why?
| | Fluorouracil | 1 | 2010 | 208 | 0.080 |
Why?
| | Sequence Analysis, DNA | 4 | 2015 | 812 | 0.080 |
Why?
| | CHO Cells | 1 | 2009 | 161 | 0.080 |
Why?
| | Genomics | 4 | 2022 | 795 | 0.080 |
Why?
| | Positive Transcriptional Elongation Factor B | 2 | 2017 | 29 | 0.080 |
Why?
| | Liver Neoplasms | 1 | 2015 | 786 | 0.080 |
Why?
| | Adenosine Deaminase | 2 | 2007 | 36 | 0.080 |
Why?
| | Fibronectins | 3 | 2009 | 133 | 0.080 |
Why?
| | Epithelial Cells | 1 | 2015 | 1096 | 0.080 |
Why?
| | Cricetinae | 1 | 2009 | 289 | 0.080 |
Why?
| | rho GTP-Binding Proteins | 1 | 2009 | 60 | 0.080 |
Why?
| | RNA Transport | 1 | 2008 | 23 | 0.080 |
Why?
| | Female | 19 | 2021 | 73465 | 0.070 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2008 | 124 | 0.070 |
Why?
| | Rabbits | 2 | 2002 | 794 | 0.070 |
Why?
| | Phosphoproteins | 1 | 1990 | 338 | 0.070 |
Why?
| | Carcinoma | 2 | 2015 | 240 | 0.070 |
Why?
| | Amanitins | 2 | 2004 | 4 | 0.070 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2013 | 801 | 0.070 |
Why?
| | Ribonucleoproteins | 1 | 2008 | 105 | 0.070 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 2 | 1998 | 24 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2014 | 1164 | 0.070 |
Why?
| | Bacteroides | 1 | 2007 | 21 | 0.070 |
Why?
| | Enhancer Elements, Genetic | 3 | 2017 | 190 | 0.070 |
Why?
| | Enzyme Activation | 2 | 2020 | 810 | 0.070 |
Why?
| | Mutant Proteins | 1 | 2007 | 103 | 0.060 |
Why?
| | Fragile X Mental Retardation Protein | 1 | 2007 | 50 | 0.060 |
Why?
| | Cell Nucleus Structures | 1 | 2006 | 4 | 0.060 |
Why?
| | Fragile X Syndrome | 1 | 2007 | 77 | 0.060 |
Why?
| | Replication Origin | 2 | 2002 | 19 | 0.060 |
Why?
| | Lung Neoplasms | 3 | 2015 | 2526 | 0.060 |
Why?
| | Oncogenes | 1 | 1986 | 116 | 0.060 |
Why?
| | Heterozygote | 1 | 2007 | 293 | 0.060 |
Why?
| | Allosteric Regulation | 1 | 2006 | 97 | 0.060 |
Why?
| | Receptors, AMPA | 1 | 2007 | 141 | 0.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 1692 | 0.060 |
Why?
| | Substrate Specificity | 2 | 1997 | 372 | 0.060 |
Why?
| | Uracil | 1 | 2005 | 31 | 0.060 |
Why?
| | Glycoproteins | 1 | 2007 | 342 | 0.060 |
Why?
| | Nucleic Acid Synthesis Inhibitors | 1 | 2004 | 16 | 0.060 |
Why?
| | DNA Repair | 2 | 1997 | 231 | 0.060 |
Why?
| | Physical Chromosome Mapping | 1 | 2004 | 20 | 0.060 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2004 | 19 | 0.060 |
Why?
| | Genes, cdc | 1 | 2004 | 11 | 0.050 |
Why?
| | Oligodeoxyribonucleotides | 2 | 1996 | 143 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2021 | 1946 | 0.050 |
Why?
| | Genetic Testing | 1 | 2007 | 462 | 0.050 |
Why?
| | Intestines | 1 | 2007 | 357 | 0.050 |
Why?
| | BRCA2 Protein | 1 | 2003 | 63 | 0.050 |
Why?
| | Antineoplastic Agents | 2 | 2013 | 2129 | 0.050 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2024 | 175 | 0.050 |
Why?
| | Phenotype | 3 | 2018 | 3196 | 0.050 |
Why?
| | RNA, Small Nuclear | 1 | 2003 | 37 | 0.050 |
Why?
| | DNA Mutational Analysis | 2 | 2015 | 399 | 0.050 |
Why?
| | Amino Acid Motifs | 1 | 2003 | 225 | 0.050 |
Why?
| | Simian virus 40 | 1 | 2002 | 24 | 0.050 |
Why?
| | Colorectal Neoplasms | 1 | 2010 | 807 | 0.050 |
Why?
| | Tumor Cells, Cultured | 2 | 2017 | 955 | 0.050 |
Why?
| | Interleukin-10 Receptor beta Subunit | 1 | 2022 | 1 | 0.050 |
Why?
| | Binding Sites, Antibody | 1 | 1982 | 42 | 0.050 |
Why?
| | Mucin-1 | 1 | 2022 | 21 | 0.050 |
Why?
| | Phospholipid Transfer Proteins | 1 | 2022 | 11 | 0.050 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2002 | 32 | 0.050 |
Why?
| | Structure-Activity Relationship | 1 | 2003 | 570 | 0.050 |
Why?
| | Operon | 1 | 1982 | 64 | 0.050 |
Why?
| | E-Selectin | 1 | 2022 | 57 | 0.050 |
Why?
| | Lectins, C-Type | 1 | 2022 | 67 | 0.050 |
Why?
| | State Medicine | 1 | 2021 | 24 | 0.050 |
Why?
| | Fucosyltransferases | 1 | 2022 | 33 | 0.050 |
Why?
| | Factor VIII | 1 | 2022 | 98 | 0.040 |
Why?
| | Ribonucleases | 2 | 2003 | 55 | 0.040 |
Why?
| | Human Genome Project | 1 | 2001 | 15 | 0.040 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2022 | 137 | 0.040 |
Why?
| | Templates, Genetic | 2 | 1996 | 63 | 0.040 |
Why?
| | HL-60 Cells | 1 | 2020 | 34 | 0.040 |
Why?
| | Cell Adhesion Molecules | 1 | 2022 | 181 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 318 | 0.040 |
Why?
| | Neoplasm Metastasis | 2 | 2015 | 658 | 0.040 |
Why?
| | Adult | 7 | 2021 | 38023 | 0.040 |
Why?
| | Genetic Variation | 2 | 2021 | 991 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2007 | 4193 | 0.040 |
Why?
| | DNA, Plant | 1 | 1999 | 15 | 0.040 |
Why?
| | Family Characteristics | 1 | 2021 | 191 | 0.040 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 1999 | 30 | 0.040 |
Why?
| | Minichromosome Maintenance Complex Component 2 | 1 | 1999 | 4 | 0.040 |
Why?
| | Genes, Plant | 1 | 1999 | 50 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 2022 | 385 | 0.040 |
Why?
| | Fatigue | 1 | 2002 | 329 | 0.040 |
Why?
| | Holoenzymes | 1 | 1999 | 24 | 0.040 |
Why?
| | RNA Helicases | 1 | 1999 | 30 | 0.040 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2002 | 242 | 0.040 |
Why?
| | Mammals | 2 | 1998 | 283 | 0.040 |
Why?
| | Arabidopsis | 1 | 1999 | 95 | 0.040 |
Why?
| | Evolution, Molecular | 3 | 2013 | 493 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 3 | 2015 | 2427 | 0.040 |
Why?
| | Carrier Proteins | 2 | 2003 | 771 | 0.040 |
Why?
| | Cell Differentiation | 1 | 1986 | 1991 | 0.040 |
Why?
| | Proteins | 3 | 2004 | 1009 | 0.040 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1775 | 0.040 |
Why?
| | Dogs | 1 | 1999 | 413 | 0.040 |
Why?
| | Peptide Initiation Factors | 1 | 1997 | 16 | 0.040 |
Why?
| | Eukaryotic Initiation Factor-4E | 1 | 1997 | 27 | 0.040 |
Why?
| | Peptide Fragments | 3 | 1998 | 706 | 0.030 |
Why?
| | Tretinoin | 2 | 1990 | 123 | 0.030 |
Why?
| | Mediator Complex | 1 | 1998 | 61 | 0.030 |
Why?
| | Glutathione Transferase | 1 | 1997 | 106 | 0.030 |
Why?
| | Nucleic Acid Hybridization | 2 | 1992 | 190 | 0.030 |
Why?
| | South Africa | 1 | 2018 | 222 | 0.030 |
Why?
| | Prognosis | 2 | 2022 | 4039 | 0.030 |
Why?
| | Exercise Therapy | 1 | 2002 | 443 | 0.030 |
Why?
| | SAM Domain and HD Domain-Containing Protein 1 | 1 | 2017 | 12 | 0.030 |
Why?
| | Spodoptera | 1 | 1997 | 40 | 0.030 |
Why?
| | Burkitt Lymphoma | 2 | 1988 | 60 | 0.030 |
Why?
| | Cell Survival | 1 | 2020 | 1120 | 0.030 |
Why?
| | Drosophila | 1 | 1998 | 154 | 0.030 |
Why?
| | Alleles | 2 | 2013 | 892 | 0.030 |
Why?
| | Pedigree | 1 | 2018 | 514 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2015 | 2189 | 0.030 |
Why?
| | Xeroderma Pigmentosum Group D Protein | 1 | 1996 | 6 | 0.030 |
Why?
| | Repetitive Sequences, Nucleic Acid | 2 | 2001 | 113 | 0.030 |
Why?
| | Critical Care | 1 | 2022 | 610 | 0.030 |
Why?
| | Mice, SCID | 1 | 2017 | 367 | 0.030 |
Why?
| | Sp1 Transcription Factor | 1 | 1996 | 24 | 0.030 |
Why?
| | Mutagenesis, Insertional | 1 | 1996 | 65 | 0.030 |
Why?
| | Pilot Projects | 1 | 2021 | 1713 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2017 | 352 | 0.030 |
Why?
| | Herpes Simplex Virus Protein Vmw65 | 1 | 1995 | 6 | 0.030 |
Why?
| | Cloning, Molecular | 2 | 1990 | 534 | 0.030 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1995 | 28 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2017 | 601 | 0.030 |
Why?
| | Trastuzumab | 1 | 2015 | 96 | 0.030 |
Why?
| | Simplexvirus | 1 | 1995 | 80 | 0.030 |
Why?
| | Mutation Rate | 1 | 2015 | 30 | 0.030 |
Why?
| | Loss of Heterozygosity | 1 | 2015 | 51 | 0.030 |
Why?
| | DNA Primase | 1 | 2015 | 47 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2015 | 99 | 0.030 |
Why?
| | Imatinib Mesylate | 1 | 2015 | 79 | 0.030 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2015 | 73 | 0.030 |
Why?
| | Dacarbazine | 1 | 2015 | 98 | 0.030 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2015 | 47 | 0.030 |
Why?
| | Tamoxifen | 1 | 2015 | 202 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2015 | 67 | 0.030 |
Why?
| | Apoptosis | 2 | 2017 | 2553 | 0.030 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2015 | 44 | 0.030 |
Why?
| | Oligonucleotide Probes | 1 | 1994 | 51 | 0.030 |
Why?
| | TATA Box | 1 | 1994 | 24 | 0.030 |
Why?
| | Blotting, Western | 1 | 1997 | 1227 | 0.030 |
Why?
| | Estrogens | 1 | 2017 | 367 | 0.030 |
Why?
| | Lentivirus | 1 | 2014 | 56 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 872 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2015 | 303 | 0.030 |
Why?
| | KCNQ2 Potassium Channel | 1 | 2014 | 10 | 0.030 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2014 | 41 | 0.030 |
Why?
| | Quinazolines | 1 | 2015 | 251 | 0.030 |
Why?
| | Uniparental Disomy | 1 | 2014 | 9 | 0.030 |
Why?
| | NAV1.2 Voltage-Gated Sodium Channel | 1 | 2014 | 8 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2014 | 12 | 0.030 |
Why?
| | Child | 3 | 2021 | 21989 | 0.030 |
Why?
| | Histone Deacetylase 1 | 1 | 2014 | 25 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 307 | 0.030 |
Why?
| | Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2014 | 26 | 0.030 |
Why?
| | Granulosa Cell Tumor | 1 | 2013 | 5 | 0.030 |
Why?
| | Pathology, Molecular | 1 | 2014 | 27 | 0.030 |
Why?
| | Family | 1 | 2018 | 671 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2015 | 389 | 0.030 |
Why?
| | Time-Lapse Imaging | 1 | 2013 | 21 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2015 | 407 | 0.030 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2013 | 48 | 0.030 |
Why?
| | Mediator Complex Subunit 1 | 1 | 2013 | 5 | 0.030 |
Why?
| | Child, Preschool | 2 | 2021 | 11105 | 0.030 |
Why?
| | Receptor, ErbB-2 | 1 | 2015 | 341 | 0.030 |
Why?
| | Piperazines | 1 | 1995 | 350 | 0.030 |
Why?
| | Gene Expression | 1 | 2018 | 1502 | 0.030 |
Why?
| | Hyperplasia | 1 | 2013 | 175 | 0.030 |
Why?
| | Retinoblastoma Protein | 1 | 2013 | 57 | 0.030 |
Why?
| | Neurosurgical Procedures | 1 | 2015 | 197 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2015 | 377 | 0.030 |
Why?
| | Molecular Weight | 2 | 1990 | 335 | 0.020 |
Why?
| | HIV | 1 | 1994 | 234 | 0.020 |
Why?
| | Male | 5 | 2021 | 67906 | 0.020 |
Why?
| | Genetics, Medical | 2 | 2004 | 26 | 0.020 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 95 | 0.020 |
Why?
| | Multimodal Imaging | 1 | 2013 | 114 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 327 | 0.020 |
Why?
| | Gene Duplication | 2 | 2004 | 68 | 0.020 |
Why?
| | CpG Islands | 2 | 2004 | 157 | 0.020 |
Why?
| | Immunoblotting | 1 | 2012 | 308 | 0.020 |
Why?
| | Exome | 1 | 2013 | 231 | 0.020 |
Why?
| | Tomography, Optical Coherence | 1 | 2013 | 213 | 0.020 |
Why?
| | Young Adult | 2 | 2021 | 13240 | 0.020 |
Why?
| | Cytochrome b Group | 1 | 1991 | 18 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2013 | 382 | 0.020 |
Why?
| | Plant Proteins | 2 | 2003 | 113 | 0.020 |
Why?
| | Dinucleoside Phosphates | 1 | 1991 | 27 | 0.020 |
Why?
| | X Chromosome | 1 | 1991 | 53 | 0.020 |
Why?
| | Middle Aged | 3 | 2021 | 33554 | 0.020 |
Why?
| | Genes, Recessive | 1 | 1991 | 78 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 366 | 0.020 |
Why?
| | Electrocardiography | 1 | 2014 | 629 | 0.020 |
Why?
| | Up-Regulation | 1 | 2013 | 843 | 0.020 |
Why?
| | Organoplatinum Compounds | 1 | 2010 | 45 | 0.020 |
Why?
| | Capecitabine | 1 | 2010 | 45 | 0.020 |
Why?
| | Intracellular Membranes | 1 | 1990 | 84 | 0.020 |
Why?
| | NADPH Oxidases | 1 | 1990 | 113 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 1276 | 0.020 |
Why?
| | Point Mutation | 2 | 2003 | 235 | 0.020 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2013 | 1081 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2475 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2013 | 614 | 0.020 |
Why?
| | Zebrafish | 1 | 2014 | 499 | 0.020 |
Why?
| | Fluorescence Recovery After Photobleaching | 1 | 2009 | 20 | 0.020 |
Why?
| | Binding, Competitive | 1 | 1989 | 202 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1917 | 0.020 |
Why?
| | DNA Restriction Enzymes | 1 | 1988 | 52 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2015 | 1080 | 0.020 |
Why?
| | Kidney | 1 | 1996 | 1475 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3569 | 0.020 |
Why?
| | Peptide Chain Initiation, Translational | 1 | 1988 | 44 | 0.020 |
Why?
| | Protein Biosynthesis | 2 | 1988 | 433 | 0.020 |
Why?
| | Translocation, Genetic | 1 | 1987 | 105 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2760 | 0.020 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2007 | 37 | 0.020 |
Why?
| | Trinucleotide Repeat Expansion | 1 | 2007 | 29 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 767 | 0.020 |
Why?
| | Deoxyribonucleases | 1 | 1986 | 24 | 0.020 |
Why?
| | DNA Damage | 1 | 2009 | 420 | 0.020 |
Why?
| | Antibodies, Phospho-Specific | 1 | 2006 | 2 | 0.020 |
Why?
| | Symbiosis | 1 | 2007 | 79 | 0.020 |
Why?
| | Gene Deletion | 1 | 2007 | 391 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7637 | 0.010 |
Why?
| | Lymphoma | 1 | 1986 | 212 | 0.010 |
Why?
| | Neutrophils | 1 | 1990 | 1238 | 0.010 |
Why?
| | Contig Mapping | 1 | 2004 | 11 | 0.010 |
Why?
| | Pseudogenes | 1 | 2004 | 18 | 0.010 |
Why?
| | Base Composition | 1 | 2004 | 78 | 0.010 |
Why?
| | Aged | 2 | 2017 | 24001 | 0.010 |
Why?
| | Pan troglodytes | 1 | 2004 | 63 | 0.010 |
Why?
| | Leukocytes, Mononuclear | 1 | 2007 | 558 | 0.010 |
Why?
| | Co-Repressor Proteins | 1 | 2003 | 18 | 0.010 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2003 | 59 | 0.010 |
Why?
| | Adenovirus E1A Proteins | 1 | 2003 | 12 | 0.010 |
Why?
| | Cohort Studies | 1 | 2014 | 5750 | 0.010 |
Why?
| | Gene Amplification | 1 | 2003 | 104 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2003 | 272 | 0.010 |
Why?
| | Antigens, Polyomavirus Transforming | 1 | 2002 | 18 | 0.010 |
Why?
| | Gene Silencing | 1 | 2003 | 195 | 0.010 |
Why?
| | Adenoviridae | 1 | 2003 | 193 | 0.010 |
Why?
| | Nucleic Acid Conformation | 1 | 2006 | 728 | 0.010 |
Why?
| | COS Cells | 1 | 2002 | 188 | 0.010 |
Why?
| | Microscopy, Immunoelectron | 1 | 2002 | 46 | 0.010 |
Why?
| | HT29 Cells | 1 | 2002 | 41 | 0.010 |
Why?
| | Adolescent | 1 | 2021 | 21574 | 0.010 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2002 | 95 | 0.010 |
Why?
| | Immunoglobulin Light Chains | 1 | 1982 | 47 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2003 | 404 | 0.010 |
Why?
| | Ecosystem | 1 | 2007 | 596 | 0.010 |
Why?
| | Schizosaccharomyces pombe Proteins | 1 | 2002 | 78 | 0.010 |
Why?
| | Bacteriophage lambda | 1 | 1982 | 88 | 0.010 |
Why?
| | Drosophila melanogaster | 1 | 2003 | 233 | 0.010 |
Why?
| | GC Rich Sequence | 1 | 2001 | 4 | 0.010 |
Why?
| | Public Sector | 1 | 2001 | 18 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 976 | 0.010 |
Why?
| | Private Sector | 1 | 2001 | 52 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 1986 | 847 | 0.010 |
Why?
| | Microscopy, Confocal | 1 | 2002 | 325 | 0.010 |
Why?
| | DNA Replication | 1 | 2002 | 238 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2007 | 879 | 0.010 |
Why?
| | Physical Fitness | 1 | 2002 | 209 | 0.010 |
Why?
| | Conserved Sequence | 1 | 2001 | 239 | 0.010 |
Why?
| | Disability Evaluation | 1 | 2002 | 290 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2015 | 10837 | 0.010 |
Why?
| | DNA Transposable Elements | 1 | 2001 | 121 | 0.010 |
Why?
| | Respiratory Function Tests | 1 | 2002 | 601 | 0.010 |
Why?
| | Drug Industry | 1 | 2001 | 111 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2001 | 523 | 0.010 |
Why?
| | Phylogeny | 1 | 2003 | 904 | 0.010 |
Why?
| | Species Specificity | 1 | 2001 | 585 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 2003 | 506 | 0.010 |
Why?
| | Heterochromatin | 1 | 1999 | 53 | 0.010 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 1986 | 630 | 0.010 |
Why?
| | Regression Analysis | 1 | 2002 | 1024 | 0.010 |
Why?
| | Chromosomes | 1 | 1999 | 107 | 0.010 |
Why?
| | Multigene Family | 1 | 1999 | 198 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1999 | 385 | 0.010 |
Why?
| | Forecasting | 1 | 2001 | 389 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2003 | 2057 | 0.010 |
Why?
| | Exercise Test | 1 | 2002 | 632 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2002 | 706 | 0.010 |
Why?
| | Cloning, Organism | 1 | 1998 | 6 | 0.010 |
Why?
| | Protein Sorting Signals | 1 | 1998 | 20 | 0.010 |
Why?
| | Genetic Complementation Test | 1 | 1998 | 67 | 0.010 |
Why?
| | Quality of Life | 1 | 2010 | 2894 | 0.010 |
Why?
| | Cations, Divalent | 1 | 1998 | 52 | 0.010 |
Why?
| | Guanosine Triphosphate | 1 | 1998 | 91 | 0.010 |
Why?
| | Heart Rate | 1 | 2002 | 824 | 0.010 |
Why?
| | Fetus | 1 | 1982 | 806 | 0.010 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1998 | 375 | 0.010 |
Why?
| | Rats | 1 | 2006 | 5648 | 0.010 |
Why?
| | Protein Conformation | 1 | 1999 | 934 | 0.010 |
Why?
| | Proteome | 1 | 2001 | 472 | 0.010 |
Why?
| | Databases, Factual | 1 | 2001 | 1357 | 0.010 |
Why?
| | Liver | 1 | 1982 | 1943 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1991 | 77 | 0.010 |
Why?
| | Exercise | 1 | 2002 | 2061 | 0.010 |
Why?
| | Prospective Studies | 1 | 2002 | 7623 | 0.000 |
Why?
| | Reference Values | 1 | 1991 | 816 | 0.000 |
Why?
| | Pregnancy | 1 | 1982 | 6771 | 0.000 |
Why?
| | DNA, Recombinant | 1 | 1988 | 47 | 0.000 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 1987 | 29 | 0.000 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 1987 | 21 | 0.000 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 1987 | 36 | 0.000 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 1987 | 45 | 0.000 |
Why?
| | Codon | 1 | 1988 | 89 | 0.000 |
Why?
| | Chickens | 1 | 1988 | 191 | 0.000 |
Why?
| | Biological Evolution | 1 | 1988 | 475 | 0.000 |
Why?
|
|
Bentley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|